Integrated solution incorporates testing
protocols and real-time test results to help ensure safer,
healthier campuses, healthcare facilities and other venues
Biocept (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, and CLEARED4, a market
leader in pandemic health and safety solutions, have partnered to
develop a system for tracking and managing COVID-19 testing
requirements and test results for Biocept customers.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210609005175/en/
The new service will leverage CLEARED4’s comprehensive health
platform, allowing organizations to incorporate customized
protocols and requirements for testing students, employees and
others. The platform will integrate results from Biocept’s
RT-PCR-based COVID-19 testing in real-time, and administrators will
be able to monitor the program and results for their organizations
via a secure dashboard.
“This partnership with CLEARED4 is a reflection of Biocept’s
ongoing commitment to assist with public health efforts during the
pandemic,” said Michael Nall, President and CEO of Biocept. “As our
customers strive to safely reopen or increase populations at
campuses, businesses, healthcare facilities and other venues, there
is an urgent need for a system to help streamline implementation of
testing protocols and track COVID-19 testing results. Our goal is
to help ease the administrative burden of complying with complex
health requirements for our customers.”
“We are pleased to partner with Biocept on this project,” said
Dr. Soumi Eachempati, co-founder and CEO of CLEARED4. “The
combination of Biocept’s COVID-19 testing and our specialized
real-time dashboard will help ensure a safer, healthier environment
for our communities. This collaboration will allow organizations to
minimize disruptions to their workplaces and prevent illnesses to
their employees. CLEARED4 is committed to helping organizations
ensure optimal compliance with changing regulations and industry
best practices.”
CLEARED4 is a turnkey platform that enables an individual’s
COVID-19 health status to be connected to any form of access
control in real-time, including venue apps or employer tools. The
flexible solution enables partners to pick any combination of
COVID-19 symptom checking, test results and vaccination data to
trigger access to a whole location, like a venue, or a specific
zone within a location. CLEARED4’s platform can be used either as a
standalone experience or as a seamlessly integrated product in the
app of any organization.
Biocept provides PCR-based COVID-19 testing, which detects the
genetic information of the virus. The company has received more
than 400,000 samples for COVID-19 testing to date for processing in
its CLIA-certified, CAP-accredited San Diego laboratory. Most
results are available within 48 hours of Biocept’s receipt of the
sample, reducing lengthy turnaround times.
About CLEARED4
CLEARED4 is the largest and most trusted health validation
platform that enables its clients and users to safely return to
businesses, schools and stadiums across America. CLEARED4 is a
patent-pending HIPAA-compliant platform, allowing partners to
connect COVID-19 health status information from any data source to
any form of ID for access control and zone management. CLEARED4 is
able to accept and validate any health pass and integrate
seamlessly into partner apps, allowing for the most flexibility on
the market.
Pioneered from medical and engineering experts, CLEARED4
connects a user’s health data to a building’s access control in
real-time enabling clients to configure what level of COVID-19
safety is needed to meet local health guidelines, including ID
verification for contract tracing, temperature checking, COVID-19
symptom monitoring, test results and now vaccination validation.
Importantly, CLEARED4 does not own nor use the data collected for
any other purpose. A user’s identity nor personal health
information is never shared with any third party.
CLEARED4 is a pioneer in the space, launching in April 2020 with
CLEARED4WORK, and now including additional vertical specific
solutions including CLEARED4CLASS, CLEARED4FANS, CLEARED4DINING and
CLEARED4TRAVEL.
CLEARED4 offers a number of solutions that have already been
adopted at organizations and venues across the country including
Madison Square Garden, Yankee Stadium, SoFI Stadium, AT&T
Stadium, corporations like Sun Chemical, Middlesex Savings Bank,
multiple hedge funds and retail shops, municipalities including
Suffolk County, real-estate companies like Oxford Properties, and
School Districts across the country from Manhasset in NY to Orange
County in CA.
About Biocept
Biocept, Inc., develops and performs molecular diagnostic assays
that provide physicians with clinically actionable information for
treating and monitoring patients diagnosed with a variety of
cancers. In addition to its broad portfolio of blood-based liquid
biopsy assays, Biocept has developed the CNSide™ cerebrospinal
fluid assay that detects cancer that has metastasized to the
central nervous system. Biocept’s patented Target Selector™
technology captures and quantitatively analyzes CSF tumor cells for
tumor-associated molecular markers, using technology first
developed for use in blood. Biocept also is leveraging its
molecular diagnostic capabilities to offer nationwide COVID-19
RT-PCR testing to support public health efforts during this
unprecedented pandemic. For more information, visit
www.biocept.com. Follow Biocept on Facebook, LinkedIn and
Twitter.
Forward-Looking Statements Disclaimer
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements regarding the potential benefits of
the collaboration between Biocept and CLEARED4 and Biocept’s
ability to provide physicians with clinically actionable
information for treating and monitoring patients diagnosed with a
variety of cancers, such statements are forward-looking, and are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The reader is cautioned
not to put undue reliance on these forward-looking statements, as
these statements are subject to numerous risks and uncertainties,
including the risk that our products and services may not perform
as expected and the risk that we will not be able to enter into
additional services agreements. These and other risks are described
in greater detail under the "Risk Factors" heading of our Quarterly
Report on Form 10-Q for the quarter ended March 31, 2021. The
effects of such risks and uncertainties could cause actual results
to differ materially from the forward-looking statements contained
in this release. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the
information contained in this press release except as required by
law. Readers are advised to review our filings with the SEC, which
can be accessed over the Internet at the SEC's website located at
www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210609005175/en/
Biocept Contacts Media: Andrea Sampson, Sampson PR Group
asampson@sampsonprgroup.com, 562-304-0301
Investors: Jody Cain, LHA Investor Relations Jcain@lhai.com,
310-691-7100
Cleared4 Media Contact PR@CLEARED4.org
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Apr 2023 to Apr 2024